The Expression of MGMT and ErbB2 in Human Glioma

被引：0

作者：

Sun Chun-ming ^{[1
]}

Wang Zhi-min ^{[1
]}

Zheng Shi-ying ^{[2
]}

Xu Qi-nian ^{[1
]}

Zhang Shi-ming ^{[1
]}

Zhou Dai ^{[1
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Peoples R China

[2] Soochow Univ, Affiliated Hosp 1, Dept Cardio Thorac Surg, Suzhou 215006, Peoples R China

来源：

2009 INTERNATIONAL CONFERENCE ON FUTURE BIOMEDICAL INFORMATION ENGINEERING (FBIE 2009) | 2009年

关键词：

Glioma: Drug-resistance gene: RT-PCR; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; BREAST-CANCER; METHYLTRANSFERASE; CHEMOTHERAPY; CELLS; O-6-BENZYLGUANINE; RESISTANCE;

D O I：

10.1109/FBIE.2009.5405896

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

This study was comparison of MGMT and ERBB2 expression in human gliomas. RT-PCR method was used to determine the mRNA levels of MGMT and ErbB2 gene in 42 clinical glioma specimens,There was significant concordance between the expression of MGMT and ErbB2(p<0.01). MGMT and ErbB are highly remarkably related each other. The results suggest that there may be in relationship among MGMT and ErbB2 expression in human gliomas which affect DNA repair resulting in drug resistance.

引用

页码：253 / +

页数：2

共 50 条

[21] ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression
Qi, Leilei
Zhang, Baotong
Zhang, Shiying
Ci, Xinpei
Wu, Qiao
Ma, Gui
Luo, Ang
Fu, Liya
King, Jamie L.
Nahta, Rita
Dong, Jin-Tang
ONCOTARGET, 2017, 8 (22) : 36054 - 36066
[22] Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
Wolfson, Eya
Goldenberg, Maria
Solomon, Shira
Frishberg, Amit
Pinkas-Kramarski, Ronit
ONCOTARGET, 2016, 7 (40) : 65320 - 65334
[23] BREAST-CANCER RESPONSE TO ADJUVANT CHEMOTHERAPY IN CORRELATION WITH ERBB2 AND P53 EXPRESSION
JACQUEMIER, J
PENAULTLLORCA, F
VIENS, P
HOUVENAEGHEL, G
HASSOUN, J
TORRENTE, M
ADELAIDE, J
BIRNBAUM, D
ANTICANCER RESEARCH, 1994, 14 (6B) : 2773 - 2778
[24] Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells
Pero, SC
Shukla, GS
Armstrong, AL
Peterson, D
Fuller, SP
Godin, K
Kingsley-Richards, SL
Weaver, DL
Bond, J
Krag, DN
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (06) : 951 - 960
[25] Aberrations of ERBB2 and TOP2A genes in breast cancer
Nielsen, Kirsten Vang
Muller, Sven
Moller, Susanne
Schonau, Andreas
Balslev, Eva
Knoop, Ann S.
Ejlertsen, Bent
MOLECULAR ONCOLOGY, 2010, 4 (02) : 161 - 168
[26] Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and structural basis for Grb7 binding to ErbB2
Ivancic, M
Daly, RJ
Lyons, BA
JOURNAL OF BIOMOLECULAR NMR, 2003, 27 (03) : 205 - 219
[27] Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and structural basis for Grb7 binding to ErbB2
Monika Ivancic
Roger J. Daly
Barbara A. Lyons
Journal of Biomolecular NMR, 2003, 27 : 205 - 219
[28] Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition
Dokmanovic, Milos
Wu, Yun
Shen, Yi
Chen, Jieqing
Hirsch, Dianne S.
Wu, Wen Jin
CANCER BIOLOGY & THERAPY, 2014, 15 (08) : 1029 - 1041
[29] Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors
Fedele, Carmine
Riccio, Gennaro
Coppola, Carmela
Barbieri, Antonio
Monti, Maria Gaia
Arra, Claudio
Tocchetti, Carlo G.
D'Alessio, Giuseppe
Maurea, Nicola
De Lorenzo, Claudia
BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (02) : 511 - 521
[30] Cerulenin suppresses ErbB2-overexpressing breast cancer by targeting ErbB2/PKM2 pathway
Lv, Sinan
Zhang, Yunwu
Song, Jiawei
Chen, Jingruo
Huang, Bohan
Luo, Yuhan
Zhao, Yuhua
MEDICAL ONCOLOGY, 2022, 40 (01)

← 1 2 3 4 5 →